1-7 of 7
Olga Samoilova, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Larry W Kwak, MD PhD, Juan Manuel Sancho, MD PhD, Seok-Goo Cho, MD, PhD, Hideyuki Nakazawa, MD PhD, Junji Suzumiya, MD PhD, Gayane Tumyan, Jin Seok Kim, MD PhD, Tobias F Menne, MD PhD FRCPath, Jose Mario Mariz, Nikolai Ilyin, DMSc, MD PhD, Wojciech Jurczak, MD PhD, Aurelio Lopez Martínez, MD, Olga Samoilova, MD, Edvard Zhavrid, MD PhD, Eduardo Yanez Ruiz, MD, Marek Trneny, MD prof, Leslie L. Popplewell, MD FRCPA, Michinori Ogura, MDPhD, Won Seog Kim, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD, Christian Buske, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-135999
Published: 2020
Journal Articles

Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients

Olga A. Gavrilina, MD PhD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Irina V. Galtseva, MD PhD, Galina A. Baskhaeva, MD PhD, Tatiana N. Obukhova, MD PhD, Julia O. Davydova, Andrey N. Sokolov, MD PhD, Ksenija I. Zarubina, MD, Kamil D Kaplanov, MD, Olga Samoilova, MD, Pervin Zeinalova, Valery Lapin, Sergey N. Bondarenko, PhDMD, Elena Borisenkova, Tatiana Konstantinova, MD PhD, Elena E. Zinina, Maria Grishunina, MD, Julia A. Chabaeva, Sergei M. Kulikov, PhD, Valery G. Savchenko, MD PhD academician, Elena Fokina
Journal: Blood
Blood (2019) 134 (Supplement_1): 5072.
https://doi.org/10.1182/blood-2019-124701
Published: 2019
Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Michinori Ogura, MDPhD, Juan Manuel Sancho, MD PhD, Seok-Goo Cho, MD PhD, Hideyuki Nakazawa, PhD MD, Junji Suzumiya, MD PhD, Gayane Tumyan, DMSc, MD PhD, Jin Seok Kim, MD PhD, Anne Lennard, MBBS,FRCP, FRCPath, Jose Mario Mariz, MD, Nikolai Ilyin, DMSc, MD PhD, Wojciech Jurczak, MDPhD, Aurelio Lopez Martinez, MD, Olga Samoilova, MD, Edvard Zhavrid, MD PhD, Eduardo Yanez Ruiz, MD, Marek Trneny, MD CSc, Leslie Popplewell, MD, Bertrand Coiffier, MD PhD, Christian Buske, MD, Won Seog Kim, MD PhD, SangJoon Lee, PhD, Sungyoung Lee, YunJu Bae, Larry W Kwak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1596.
https://doi.org/10.1182/blood-2018-99-110334
Published: 2018
Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 691.
https://doi.org/10.1182/blood-2018-99-111370
Published: 2018
Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 784.
https://doi.org/10.1182/blood-2018-99-112988
Published: 2018
Journal Articles

MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL

Olga A. Gavrilina, MD PhD, Elena N. Parovichnikova, MD PhD, Vera V. Troitskaya, MD PhD, Galina A. Baskhaeva, MD, Andrey N. Sokolov, MD, Ksenija I. Zarubina, MD, Elena O. Gribanova, Irina V. Galtseva, PhD, Tatiana N. Obukhova, MD PhD, Kamil D Kaplanov, Olga Samoilova, MD, Sergey N. Bondarenko, PhD MD, Elena Borisenkova, Valery Lapin, Pervin Zeinalova, Elena E. Zinina, Ekaterina N. Zotina, Tatiana Konstantinova, MD PhD, Mikhail Yu. Drokov, MD PhD, Sergei M. Kulikov, PhD, Valery G. Savchenko, MD PhD academician
Journal: Blood
Blood (2018) 132 (Supplement 1): 5185.
https://doi.org/10.1182/blood-2018-99-116318
Published: 2018
Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Paula Cramer, MD, Fatih Demirkan, MD, Graeme Fraser, MD, Alexander Pristupa, MD, Nancy L Bartlett, MD, Marie-Sarah Dilhuydy, MD, Javier Loscertales, Abraham Avigdor, MD, Simon A. Rule, MD, Olga Samoilova, MD, Andre Goy, MD, Siddhartha Ganguly, MD, Italo Poggesi, ChemD, Silvia Maria Lavezzi, Giuseppe De Nicolao, Jan de Jong, PhD, Martine Neyens, Mariya Salman, PhD, Angela Howes, PhD, Michelle Mahler, MD
Journal: Blood
Blood (2016) 128 (22): 4403.
https://doi.org/10.1182/blood.V128.22.4403.4403
Published: 2016